Suppr超能文献

低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体介导尿激酶原的细胞摄取。

Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.

作者信息

Kounnas M Z, Henkin J, Argraves W S, Strickland D K

机构信息

Biochemistry Laboratory, American Red Cross, Rockville, Maryland 20855.

出版信息

J Biol Chem. 1993 Oct 15;268(29):21862-7.

PMID:7691818
Abstract

The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. Previous work has shown that LRP is responsible for mediating the internalization of urinary-type plasminogen activator (uPA) complexed to plasminogen activator inhibitor type I (PAI-1) (Nykjaer et al., 1992; Herz et al., 1992). The current study indicates that pro-urokinase (pro-uPA) and two chain urokinase (tc-uPA) bind directly to purified LRP, and that LRP mediates their internalization and degradation in Hep G2 cells. In vitro binding assays demonstrated that pro-uPA and tc-uPA bind to purified LRP with affinities (Kd = 45 and 60 nM, respectively) that are approximately 15 to 20-fold weaker than the affinity of uPA.PAI-1 complex for LRP (Kd = 3 nM). Competitive binding experiments revealed that pro-uPA and tc-uPA completely inhibit binding of uPA.PAI-1 complexes to purified LRP. The binding of 125I-pro-uPA to LRP is blocked by the 39-kDa receptor-associated protein, but not by an amino-terminal fragment of uPA, which is known to block binding of uPA to the urokinase receptor. 125I-Pro-uPA can be internalized and degraded by Hep G2 cells independent of PAI-1. Both the internalization and degradation are completely blocked by receptor-associated protein or affinity-purified LRP antibodies, indicating that LRP is mediating this process. These processes are also blocked by the amino-terminal fragment, which suggests that the favored pathway for uPA metabolism is initial binding to the urokinase receptor, followed by ligand transfer to LRP, then internalization leading to degradation.

摘要

低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体(LRP)是一种大型细胞表面受体,由一条515 kDa的重链和一条85 kDa的轻链组成,轻链是从600 kDa的前体经蛋白水解衍生而来。先前的研究表明,LRP负责介导与I型纤溶酶原激活物抑制剂(PAI-1)复合的尿激酶型纤溶酶原激活物(uPA)的内化(尼耶尔等人,1992年;赫茨等人,1992年)。当前研究表明,单链尿激酶型纤溶酶原激活物(pro-uPA)和双链尿激酶(tc-uPA)直接结合纯化的LRP,并且LRP介导它们在肝癌细胞系(Hep G2)中的内化和降解。体外结合试验表明,pro-uPA和tc-uPA与纯化的LRP结合,其亲和力(解离常数分别为45和60 nM)比uPA-PAI-1复合物与LRP的亲和力(解离常数=3 nM)弱约15至20倍。竞争性结合实验表明,pro-uPA和tc-uPA完全抑制uPA-PAI-1复合物与纯化的LRP的结合。125I-pro-uPA与LRP的结合被39 kDa的受体相关蛋白阻断,但不被已知可阻断uPA与尿激酶受体结合的uPA氨基末端片段阻断。125I-pro-uPA可被Hep G2细胞内化和降解,且不依赖于PAI-1。内化和降解均被受体相关蛋白或亲和纯化的LRP抗体完全阻断,表明LRP介导了这一过程。这些过程也被氨基末端片段阻断,这表明uPA代谢的有利途径是首先与尿激酶受体结合,然后配体转移至LRP,接着内化导致降解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验